Efficacy of rabeprazole (Razo®) in the treatment of various clinical variants of GERD: results from the GERBERA study
V. V. Tsukanov,
M. A. Cherepnin,
A. V. Vasyutin,
J. L. Tonkikh,
E. V. Kasparov,
N. A. Maslennikova,
N. V. Pavlova https://doi.org/10.21518/2079-701X-2022-16-7-28-35
Abstract
Introduction. Gastroesophageal reflux disease (GERD) is extremely common in the structure of gastroenterological diseases. Aim. To conduct a prospective observational post-marketing study of rabeprazole (Razo®) 20 mg taking once daily in patients with non-erosive reflux disease (NERD) after 2 and 4 weeks of therapy and esophagitis stage A and B after 4 weeks of therapy (GERBERA).
Materials and methods. 75 patients with GERD were included in the study (36 men and 39 women, mean age 41.7 ± 1.5 years). Clinical examination with the completion of standard questionnaires, assessment of the quality of life of patients were performed at three visits: before the start of the treatment, after 2 and 4 weeks of therapy. Fibroesophagogastroduodenoscopy was performed in all patients before treatment and in patients with esophagitis after 4 weeks of therapy. All patients received rabeprazole (Razo®) at a dose of 20 mg once a day for the treatment of GERD. The diagnosis of heartburn and sour eructation was carried out according to the recommendations of the Montreal Consensus, the diagnosis of esophagitis was performed based on the Los Angeles classification.
Results and discussion. Among patients with NERD, 74.1% of patients responded to Razo® therapy after 2 weeks of treatment, after 4 weeks the proportion of responders increased to 94.4% (p = 0.008). Healing of erosions after 4 weeks was observed in 90.5% of patients with esophagitis. Razo® therapy was accompanied by a pronounced improvement in GERD patients in all parameters of quality of life and patient satisfaction with the results of Razo® treatment.
Conclusion. Based on the results of our study, we obtained high efficacy of Razo® at a dose of 20 mg once a day for the treatment of patients with NERD and erosive esophagitis.
Supporting agencies: The research was carried out with the financial support of the company “Dr. Reddy’s Laboratories”
About the Authors
V. V. Tsukanov
Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Vladislav V. Tsukanov - Dr. Sci. (Med.), Professor, Head of the Clinical Department of the Digestive System Pathology of Adults and Children, Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”.
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022.
M. A. Cherepnin
Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Mikhail A. Cherepnin - Junior Research Fellow of the Clinical Department of the Digestive System Pathology of Adults and Children, Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”.
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022.
A. V. Vasyutin
Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Alexandr V. Vasyutin - Cand. Sci. (Med.), Senior Research Fellow of the Clinical Department of the Digestive System Pathology of Adults and Children, Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”.
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022.
J. L. Tonkikh
Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Julia L. Tonkikh - Cand. Sci. (Med.), Leading Research Fellow of the Clinical Department of the Digestive System Pathology of Adults and Children, Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”.
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022.
E. V. Kasparov
Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Edward V. Kasparov - Dr. Sci. (Med.), Professor, Director of the Scientific Research Institute of Medical Problems of the North, Deputy Director, Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences, Separate Subdivision “Scientific Research Institute of medical problems of the North”.
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022.
N. A. Maslennikova
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Nadezhda A. Maslennikova - Cand. Sci. (Med.), Assistant of the Department of Infectious Diseases, Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky.
1, Partizan Zheleznyak St., Krasnoyarsk, 660022.
N. V. Pavlova
Dr. Reddy’s Laboratories Ltd
Russian Federation
Russian Federation
Nadezhda V. Pavlova - Cand. Sci. (Med.), Medical Department, Dr. Reddy’s Laboratories Ltd.
20, Bldg. 1, Ovchinnikovskaya Emb., Moscow, 115035.
References
1. Yadlapati R., Gyawali C.P., Pandolfino J.E., CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. заменить на 2022;20(5):984–994. https://doi.org/10.1016/j.cgh.2022.01.025.
2. Eusebi L.H., Ratnakumaran R., Yuan Y., Solaymani-Dodaran M., Bazzoli F., Ford A.C. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. https://doi.org/10.1136/gutjnl-2016-313589.
3. Lazebnik L.B., Masharova A.A., Bordin D.S., Vasil’ev Y.V., Tkachenko E.I., Abdulkhakov R.A. et al. Results of a multicenter trial “Epidemiology of Gastroesophageal Reflux Disease in Russia” (MEGRE). Terapevticheskii Arkhiv. 2011;83(1):45–50. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/30789.
4. Fass R., Boeckxstaens G.E., El-Serag H., Rosen R., Sifrim D., Vaezi M.F. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021;7(1):55. https://doi.org/10.1038/s41572-021-00287-w.
5. Zerbib F., Bredenoord A.J., Fass R., Kahrilas P.J., Roman S., Savarino E. et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021;33(4):e14075. https://doi.org/10.1111/nmo.14075.
6. Rettura F., Bronzini F., Campigotto M., Lambiase C., Pancetti A., Berti G. et al. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne). 2021;8:765061. https://doi.org/10.3389/fmed.2021.765061.
7. Jung D.H., Huh C.W., Lee S.K., Park J.C., Shin S.K., Lee Y.C. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(2):165–175. https://doi.org/10.5056/jnm20161.
8. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920. https://doi.org/10.1111/j.1572-0241.2006.00630.x.
9. Modlin I.M., Hunt R.H., Malfertheiner P., Moayyedi P., Quigley E.M., Tytgat G.N. et al. Diagnosis and management of non-erosive reflux disease – the Vevey NERD Consensus Group. Digestion. 2009;80(2):74-88. Available at: https://pubmed.ncbi.nlm.nih.gov/16928254/.
10. Modlin I.M., Hunt R.H., Malfertheiner P., Moayyedi P., Quigley E.M., Tytgat G.N. et al. Non-erosive reflux disease – defining the entity and delineating the management. Digestion. 2008;78(Suppl. 1):1–5. https://doi.org/10.1159/000151248.
11. Stanghellini V., Chan F.K., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., Talley N.J. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380–1392. https://doi.org/10.1053/j.gastro.2016.02.011.
12. Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6):1393–1407. https://doi.org/10.1053/j.gastro.2016.02.031.
13. Lundell L.R., Dent J., Bennett J.R., Blum A.L., Armstrong D., Galmiche J.P. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–180. https://doi.org/10.1136/gut.45.2.172.
14. Miner P.Jr, Orr W., Filippone J., Jokubaitis L., Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332–1339. Available at: https://pubmed.ncbi.nlm.nih.gov/12094846/.
15. Kahrilas P.J., Miner P., Johanson J., Mao L., Jokubaitis L., Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50(11):2009–2018. https://doi.org/10.1007/s10620-005-3000-3.
16. Miwa H., Sasaki M., Furuta T., Koike T., Habu Y., Ito M. et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26(1):69–77. https://doi.org/10.1111/j.1365-2036.2007.03350.x.
17. Cutler A., Robinson M., Murthy A., Delemos B. Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. Dig Dis Sci. 2010;55(2):338–345. https://doi.org/10.1007/s10620-009-0864-7.
18. Caos A., Moskovitz M., Dayal Y., Perdomo C., Niecestro R., Barth J. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. Am J Gastroenterol. 2000;95(11):3081–3088. Available at: https://pubmed.ncbi.nlm.nih.gov/11095321/.
19. Caos A., Breiter J., Perdomo C., Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22(3):193–202. https://doi.org/10.1111/j.1365-2036.2005.02555.x.
20. Becher A., El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34(6):618–627. https://doi.org/10.1111/j.1365-2036.2011.04774.x.
21. Dickman R., Boaz M., Aizic S., Beniashvili Z., Fass R., Niv Y. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17(4):387–394. https://doi.org/10.5056/jnm.2011.17.4.387.
22. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-4-70-97.
23. Pace F., Coudsy B., DeLemos B., Sun Y., Xiang J., LoCoco J. et al. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. Eur J Gastroenterol Hepatol. 2011;23(10):845–851. https://doi.org/10.1097/MEG.0b013e32834991b7.
Review
For citations:
Tsukanov VV, Cherepnin MA, Vasyutin AV, Tonkikh JL, Kasparov EV, Maslennikova NA, Pavlova NV. Efficacy of rabeprazole (Razo®) in the treatment of various clinical variants of GERD: results from the GERBERA study. Meditsinskiy sovet = Medical Council. 2022;(7):28-35. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-7-28-35
Views:
7036
Email this article 